Telomerase: biology and phase I trials

The Lancet Oncology
Lloyd R Kelland

Abstract

In normal somatic cells, the ends of chromosomes (the telomeres) shorten with each cell division. By contrast, in tumour cells, telomere length is maintained, generally through the reactivation of the reverse transcriptase enzyme, telomerase. At least three applications relating to telomeres and telomerase have been proposed: in cancer diagnosis and prognosis (especially through measurements of the catalytic component of telomerase, hTERT) and as a means of monitoring tumour response to therapy; as an aid to tissue engineering; and inhibition as a cancer therapeutic strategy. Mouse knockout, hTERT dominant negative, and antisense experiments suggest that telomerase inhibitors will confer anticancer activity, especially in tumours with short telomeres. Inhibitory strategies have focused on antisense molecules, inhibitors of reverse transcriptases, and small molecules able to interact with and stabilise four-stranded (G-quadruplex) structures formed by telomeres. Clinical trials involving telomerase inhibitors require careful consideration compared to those looking at conventional anticancer cytotoxic drugs.

References

Apr 18, 1991·Nature·E H Blackburn
Aug 30, 1990·Nature·N D HastieR C Allshire
Sep 1, 1995·Science·J FengJ Yu
Feb 20, 1997·Nature·B van Steensel, T de Lange
Jul 4, 1997·Journal of Medicinal Chemistry·D SunL H Hurley
Aug 1, 1997·Nucleic Acids Research·G M Coviello-McLaughlin, K R Prowse
Apr 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A M BurgerD R Newell
Dec 31, 1997·Journal of the National Cancer Institute·G M ClarkN W Kim
Nov 21, 1998·Journal of Medicinal Chemistry·P J PerryS Neidle
Dec 10, 1998·Nature Medicine·J L Mergny, C Hélène
Mar 31, 1999·Proceedings of the National Academy of Sciences of the United States of America·J ZhuE H Blackburn
May 14, 1999·Drug Discovery Today·A E Pitts, D R Corey
May 25, 1999·Cell·J D GriffithT de Lange
Jun 11, 1999·Journal of Cellular Physiology·S E Holt, J W Shay
Jun 22, 1999·Chemistry & Biology·S E HamiltonD R Corey
Sep 25, 1999·Bioorganic & Medicinal Chemistry Letters·R J HarrisonS Neidle
Sep 29, 1999·Genes & Development·X ZhangM O Robinson
Dec 10, 1999·Proceedings of the National Academy of Sciences of the United States of America·B HerbertD R Corey
Jan 27, 2000·Cell·D Hanahan, R A Weinberg
Feb 26, 2000·Carcinogenesis·R R Reddel
Mar 11, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M D Garrett, P Workman
Apr 25, 2000·Annual Review of Medicine·V UrquidiS Goodison
Nov 9, 2000·Current Biology : CB·S Smith, T de Lange
Nov 18, 2000·Nature·E H Blackburn
Nov 23, 2000·Nature·R A DePinho

❮ Previous
Next ❯

Citations

Dec 18, 2001·Biopolymers·S Neidle, M A Read
May 12, 2005·Blood Reviews·Daniel V T Catenacci, Gary J Schiller
Oct 5, 2010·Biochemistry·Nihar RanjanDev P Arya
Aug 10, 2004·Nature Genetics·Koei ChinStephen J Lockett
Mar 6, 2003·Reviews in Clinical and Experimental Hematology·Deepak GuptaKenneth C Anderson
May 15, 2004·Journal of Anti-aging Medicine·Ali Ahmed, Trygve O Tollefsbol
Jun 18, 2002·The Lancet Oncology·James A McCaulE Kenneth Parkinson
Jul 3, 2007·British Journal of Pharmacology·P Phatak, A M Burger
May 26, 2004·Leukemia Research·Srdan VerstovsekMaher Albitar
May 2, 2006·Cancer Letters·Angelika M Burger
Jan 5, 2002·Expert Opinion on Investigational Drugs·P J PerryT C Jenkins
Oct 24, 2007·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Kathleen E HandsJan M Bruder
Oct 26, 2002·Cancer Cell·Jerry W Shay, Woodring E Wright
Jun 15, 2006·Nature Reviews. Drug Discovery·Jerry W Shay, Woodring E Wright
Feb 28, 2003·Molecular Pharmacology·Annamaria BiroccioGabriella Zupi
Dec 3, 2003·Annals of Medicine·Eric Kenneth Parkinson
Jan 22, 2003·Journal of the American Geriatrics Society·Ali Ahmed, Trygve Tollefsbol
Jul 17, 2020·International Journal of Biological Macromolecules·Jiequan WangXinhua Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Lloyd R Kelland
Proceedings of the National Academy of Sciences of the United States of America
R Hodes
© 2022 Meta ULC. All rights reserved